PTHLH and intrahepatic cholangiocarcinoma: The upregulated expression of oncogenic PTHLH is associated with poor prognosis owing to its role in promoting tumour initiation, growth, angiogenesis, metastasis, and chemoresistance in pancreatic [19], colorectal [18], intrahepatic cholangiocarcinoma [45], head and neck [46], osteosarcoma [47], and breast cancers [17,48].